CTN-0080: Medication Treatment for Opioid Use Disorder in Expectant Mothers (MOMs): A Pragmatic Randomized Trial Comparing Two Buprenorphine Formulations (NIH HEAL Initiative)

T. John Winhusen, PhD
Lead Investigator

University of Cincinnati
Addiction Sciences Division

The growing opioid-use epidemic in the U.S. has been associated with a significant increase in the prevalence of pregnant opioid-dependent women and neonatal abstinence syndrome, which is associated with adverse health effects for the infant and with costly hospitalizations. Maintenance with sublingual (SL) buprenorphine (BUP) is efficacious for opioid use disorder but has disadvantages that may be heightened in pregnant women including the potential for poor adherence, treatment dropout, and negative maternal/fetal effects associated with daily BUP peak-trough cycles. Extended release (XR) formulations may address some of these disadvantages. The primary objective of CTN-0080 is to evaluate the impact of treating opioid use disorder in pregnant women with BUP-XR, compared to BUP-SL, on maternal-infant outcomes. Testing a conceptual model of the mechanisms by which BUP-XR may improve maternal-infant outcomes, relative to BUP-SL, is a secondary trial objective.

Funded by the NIH HEAL InitiativeSM.

    Node Involvement

    Lead Node(s):

  • Ohio Valley Node

  • All Participating Nodes:

  • Appalachian Node
  • Florida Node Alliance
  • Greater Intermountain Node
  • New England Consortium
  • Ohio Valley Node
  • Pacific Northwest Node
  • Southern Consortium Node
  • Western States Node